

Figure 1






Figure 2

Malignant Breast 96102003G H95C30




Malignant Breast 9609C033R H95C30



Normal Breast 9712C030G H95C30



MB8 Cell Line H95C30



FOIb01-20552660

Figure 3

09975502-101101




Figure 4

TOTOT"205/660





Figure 5

TOTFOI 2055/660







Figure 6

00552660-107707



Polyclonal Antisera, 1:5000



Monoclonal Antibodies 1:50

Figure 6 (cont'd)

09975502-101101




Figure 7



101101 2055Z660





Figure 8

TOTOT-2055/660




Figure 9

00975502.101101




Figure 10

09975502-101101







Figure 11

007550.101101




anti-BU101.3, 10923, 1:5000  
sample reduced and boiled




anti-MAM.1, 10931, 1:5000  
sample reduced and boiled

TOTOT 20552660



Polyclonal Antibody 10923  
anti-BU101.3



Polyclonal Antibody 10931  
anti-MAM.1

Figure 13

FOI 20552660




Figure 14

095550-101




Figure 15




**FIGURE 16**

Met Lys Leu Ser Val Cys Leu Leu Leu Val Thr Leu Ala Leu Cys  
Cys  
1 5 10 15  
Tyr Gln Ala Asn Ala Glu Phe Cys Pro Ala Leu Val Ser Glu Leu  
Leu  
20 25 30  
Asp Phe Phe Phe Ile Ser Glu Pro Leu Phe Lys Leu Ser Leu Ala  
Lys  
35 40 45  
Phe Asp Ala Pro Pro Glu Ala Val Ala Ala Lys Leu Gly Val Lys  
Arg  
50 55 60  
Cys Thr Asp Gln Met Ser Leu Gln Lys Arg Ser Leu Ile Ala Glu  
Val  
65 70 75  
80  
Leu Val Lys Ile Leu Lys Lys Cys Ser Val  
85 90

093502-101101  
F01T01-20552660

### Assembly of BS106 from Individual Expressed Tags



### **Figure 18A**

#### **>BS106 consensus**

CGGCTCGAGCTCTTAGGCTTTGAAGCATTTTTGTCTGTGCTCCCTGATCTTCAGGTCACCACC A  
TGAAGTTCTTAGCAGTCCTGGTACTCTTGGGAGTTTCCATCTTTCTGGTCTCTGCCCAGAATCC  
GACAACAGCTGCTCCAGCTGACACGTATCCAGCTACTGGTCCTGCTGATGATGAAGCCCCTGA  
TGCTGAAACCACTGCTGCTGCAACCACTGCGACCAC TGCTGCTCCTACCACTGCAACCACCGC  
TGCTTCTACCACTGCTCGTAAAGACATTCCAGTTTTACCCAAATGGGTTGGGGATCTTCCGAAT  
GGTAGAGTGTGTCCCTGAGATGGAATCAGCTTGAGTCTTCTGCAATTGGTCACAACCTATTCAT  
GCTTCCTGTGATTTTCATCCAACCTACTTACCTTGCCTACGATATCCCCTTTATCTCTAATCAGTTT  
ATTTTCTTTCAAATAAAAAATAACTATGAGCAACATA AAAAAAAAAAAAA


### **Figure 18B**

#### **>BS106 translation**

MKFLAVLVLLGVSI FLVSAQNPTTAAPADTYPATGPADDEAPDAETTAAATTATTAAPTATTAA  
STTARKDIPVLPKWVGDL PNGRVCP.

09975502.101101  
TOTOT"2055/660

Figure 19A



\* Expression not detectable

Figure 19B









Figure 19C



TOTAL 20552660

**Figures 20 A-D**



Correlations Between Marker Expression and Clinical and Molecular Parameters

	BU101	BS106	Mammaglobin	CK19	
<b>T Stage</b>	0.003 (NS)	-0.13 (NS)	-0.03 (NS)	-0.03 (NS)	N=95
<b>Grade</b>	-0.14 (NS)	0.12 (NS)	0.03 (NS)	0.06 (NS)	N=90
<b>N Stage</b>	0.05 (NS)	0.06 (NS)	0.04 (NS)	0.19 (NS)	N=85
<b>Nodes +</b>	-0.02 (NS)	0.01 (NS)	0.05 (NS)	0.23 (NS)	N=85
<b>ER</b>	-0.18 (NS)	-0.10 (NS)	<b>-0.23 (p=0.02)</b>	-0.18 (NS)	N=99
<b>PR</b>	-0.18 (NS)	-0.10 (NS)	<b>-0.23 (p=0.02)</b>	-0.18 (NS)	N=99
<b>HER2</b>	-0.12 (NS)	<b>0.36 (p=0.003)</b>	0.11 (NS)	0.02 (NS)	N=67
<b>P53</b>	-0.19 (NS)	-0.16 (NS)	-0.02 (NS)	-0.14 (NS)	N=77
<b>BU101</b>	-----	-0.05 (NS)	<b>0.37 (p=0.0001)</b>	-0.04 (NS)	N=101
<b>BS106</b>	-0.05 (NS)	-----	0.004 (NS)	0.07 (NS)	N=101
<b>Mamm</b>	<b>0.37 (p=0.0001)</b>	0.004 (NS)	-----	0.07 (NS)	N=101

Pearson product moment correlations were calculated between each pair of variables. The only significant relationships observed are bolded and have included p values. **NS= not significant**